Effect of different doses of dexmedetomidine on the median effective concentration of propofol during gastrointestinal endoscopy: a randomized controlled trial
British Journal of Clinical Pharmacology · 2023
DOI: 10.1111/bcp.15647 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Hai-Yan Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China. Hauptthemen laut MEDLINE: Propofol, Dexmedetomidine, Anesthesia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
Dexmedetomidine could be an ideal adjuvant to propofol during gastrointestinal endoscopy because it provides both analgesia and sedation without respiratory depression. This study investigates the effect of different doses of dexmedetomidine on the median effective concentration of propofol during gastrointestinal endoscopy.
Methods
Ninety adult patients were randomly assigned to Group Control, Group DEX0.5 (0.5 μg/kg dexmedetomidine) or Group DEX1.0 (1.0 μg/kg dexmedetomidine). Anaesthesia during endoscopy was implemented by plasma target‐controlled infusion (TCI) of propofol with different doses of dexmedetomidine. TCI concentration of the first patient for each group was 2.5 μg/mL and the consecutive adjacent concentration gradient was 0.5 μg/mL. Median effective concentration (EC 50 ) of propofol by TCI for gastrointestinal endoscopy was determined by using the modified Dixon's up‐and‐down method. Cardiovascular variables were also measured.
Results
EC 50 of propofol by TCI and 95% confidence interval (CI) for gastrointestinal endoscopy were 3.77 (3.48–4.09), 2.51 (2.27–2.78) and 2.10 (1.90–2.33) μg/mL in Group Control, Group DEX0.5 and Group DEX1.0, respectively. The average percent change from heart rate (HR) baseline was 2.8 (8.9), −7.4 (7.7) and −10.5 (8.8) ( P < .001), and the average percent change from mean arterial pressure (MAP) baseline was −10.6 [−24.7; 3.5], −9.5 [−29.2; 11.4] and −4.0 [−27.3; 15.5] ( P = .034) in Group Control, Group DEX0.5 and Group DEX1.0, respectively.
Conclusions
Dexmedetomidine reduced the EC 50 of propofol by TCI. A 0.5–1 μg/kg dose of dexmedetomidine caused a decrease in HR without bradycardia. The decrease in dosage of propofol with increasing doses of dexmedetomidine caused more stable MAP. Dexmedetomidine is an ideal adjuvant drug to propofol during gastrointestinal endoscopy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
ORCID-Profile: Jin-Chao Song
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, H. Y., Deng, F., Tang, S. H., Liu, W., Yang, H., & Song, J. C. (2023). Effect of different doses of dexmedetomidine on the median effective concentration of propofol during gastrointestinal endoscopy: a randomized controlled trial. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15647
Vancouver
Chen HY, Deng F, Tang SH, Liu W, Yang H, Song JC. Effect of different doses of dexmedetomidine on the median effective concentration of propofol during gastrointestinal endoscopy: a randomized controlled trial. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15647
BibTeX
@article{Chen2023,
author = {Chen, Hai-Yan and Deng, Fang and Tang, Shu-Heng and Liu, Wen and Yang, Hua and Song, Jin-Chao},
title = {Effect of different doses of dexmedetomidine on the median effective concentration of propofol during gastrointestinal endoscopy: a randomized controlled trial},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1111/bcp.15647}
}
EUVIMED